## Vito Pistoia

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7433916/publications.pdf

Version: 2024-02-01

123 papers 6,111 citations

43 h-index 76900 74 g-index

127 all docs

127 docs citations

127 times ranked

10232 citing authors

#	Article	IF	CITATIONS
1	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD $<$ sup $>+sup>. Oncolmmunology, 2018, 7, e1458809.$	4.6	59
2	IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis. Oncolmmunology, 2018, 7, e1397249.	4.6	6
3	Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model. Oncolmmunology, 2018, 7, e1378843.	4.6	88
4	CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2722.	4.8	124
5	Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors. Journal of Immunology Research, 2018, 2018, 1-10.	2.2	7
6	Human $\hat{I}^3\hat{I}$ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias. Frontiers in Immunology, 2018, 9, 984.	4.8	58
7	<i>CHL1</i> gene acts as a tumor suppressor in human neuroblastoma. Oncotarget, 2018, 9, 25903-25921.	1.8	24
8	The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment. Journal of Leukocyte Biology, 2017, 102, 711-717.	3.3	54
9	Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma. Cancer Biology and Therapy, 2017, 18, 285-289.	3.4	10
10	MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. Oncolmmunology, 2017, 6, e1316439.	4.6	33
11	Mesenchymal stromal cells and autoimmunity. International Immunology, 2017, 29, 49-58.	4.0	61
12	Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective. Trends in Molecular Medicine, 2017, 23, 1156-1175.	6.7	40
13	Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma. Molecular Medicine, 2016, 22, 694-704.	4.4	81
14	Isolation and characterization of renal cancer stem cells from patient-derived xenografts. Oncotarget, 2016, 7, 15507-15524.	1.8	20
15	Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients. Journal of Immunology Research, 2016, 2016, 1-6.	2.2	10
16	Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy. Journal of Immunology Research, 2016, 2016, 1-7.	2.2	19
17	Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases. Journal of Immunology Research, 2016, 2016, 1-14.	2.2	104
18	A Promyelocytic Leukemia Protein–Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma. Clinical Cancer Research, 2016, 22, 3398-3409.	7.0	8

#	Article	IF	CITATIONS
19	Restricted ROC curves are useful tools to evaluate the performance of tumour markers. Statistical Methods in Medical Research, 2016, 25, 294-314.	1.5	7
20	IL-17 superfamily cytokines modulate normal germinal center B cell migration. Journal of Leukocyte Biology, 2016, 100, 913-918.	3.3	36
21	CD4 <sup>+</sup> CD25 <sup>hi</sup> CD127 <sup>â^²</sup> Treg and CD4 <sup>+</sup> CD45R0 <sup>+</sup> CD49b <sup>+</sup> LAG3 <sup>+</sup> Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma. Oncolmmunology, 2016, 5, e1249553.	4.6	17
22	Editorial: Targeting JAM-C on mantle cell lymphoma B cells: time for clinical testing?. Journal of Leukocyte Biology, 2016, 100, 835-837.	3.3	0
23	Exosomes from human mesenchymal stem cells conduct aerobic metabolism in term and preterm newborn infants. FASEB Journal, 2016, 30, 1416-1424.	0.5	63
24	IL12RB2 Polymorphisms correlate with risk of lung adenocarcinoma. Immunobiology, 2016, 221, 291-299.	1.9	6
25	PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncolmmunology, 2016, 5, e1064578.	4.6	91
26	Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor. World Journal of Gastroenterology, 2016, 22, 3496-3501.	3.3	3
27	$\hat{I}^{3\hat{I}'}$ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR- $\hat{I}^{2}$ +/CD19+ lymphocytes. Blood, 2015, 125, 2349-2358.	1.4	224
28	NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model. Cells, 2015, 4, 520-537.	4.1	99
29	Expression of <i>FOXP3 </i> , <i>CD14 </i> , and <i>ARG1 </i> in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival. BioMed Research International, 2015, 2015, 1-10.	1.9	6
30	IL-10 and ARG-1 Concentrations in Bone Marrow and Peripheral Blood of Metastatic Neuroblastoma Patients Do Not Associate with Clinical Outcome. Journal of Immunology Research, 2015, 2015, 1-9.	2.2	16
31	Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models. Oncotarget, 2015, 6, 11806-11819.	1.8	127
32	Cancer associated fibroblasts in hematological malignancies. Oncotarget, 2015, 6, 2589-2603.	1.8	46
33	Evaluation of bone marrow as a metastatic site of human neuroblastoma. Annals of the New York Academy of Sciences, 2015, 1335, 23-31.	3.8	25
34	Accelerated Tumor Progression in Mice Lacking the ATP Receptor P2X7. Cancer Research, 2015, 75, 635-644.	0.9	157
35	The P2X7 receptor is a key modulator of the PI3K/GSK3 $\hat{I}^2$ /VEGF signaling network: evidence in experimental neuroblastoma. Oncogene, 2015, 34, 5240-5251.	<b>5.</b> 9	149
36	Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. Journal of Controlled Release, 2015, 211, 44-52.	9.9	49

3

#	Article	IF	CITATIONS
37	CD56brightCD16â^' NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation. Journal of Immunology, 2015, 195, 965-972.	0.8	111
38	The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma. Leukemia, 2015, 29, 958-967.	7.2	31
39	Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Annals of the New York Academy of Sciences, 2015, 1335, 10-22.	3.8	47
40	Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma. Oncolmmunology, 2015, 4, e1030560.	4.6	21
41	Mesenchymal stromal cells and immunity: Introductory overview. Immunology Letters, 2015, 168, 127-128.	2.5	10
42	Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells. Blood, 2015, 126, 1849-1849.	1.4	16
43	Intratumoral diversity of telomere length in individual neuroblastoma tumors. Oncotarget, 2015, 6, 7493-7503.	1.8	37
44	A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. Oncotarget, 2015, 6, 25602-25618.	1.8	79
45	CD38 and bone marrow microenvironment. Frontiers in Bioscience - Landmark, 2014, 19, 152.	3.0	26
46	ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death and Disease, 2014, 5, e1135-e1135.	6.3	102
47	Role of Fractalkine/CX3CL1 and Its Receptor in the Pathogenesis of Inflammatory and Malignant Diseases with Emphasis on B Cell Malignancies. Mediators of Inflammation, 2014, 2014, 1-10.	3.0	71
48	Unveiling the role of TNF â€Î± in mesenchymal stromal cellâ€mediated immunosuppression. European Journal of Immunology, 2014, 44, 352-356.	2.9	10
49	Binding of HLA-G to ITIM-Bearing Ig-like Transcript 2 Receptor Suppresses B Cell Responses. Journal of Immunology, 2014, 192, 1536-1546.	0.8	137
50	Telomere shortening and increased oxidative stress are restricted to venous tissue in patients with varicose veins: A merely local disease?. Vascular Medicine, 2014, 19, 125-130.	1.5	5
51	IL-27 Driven Upregulation of Surface HLA-E Expression on Monocytes Inhibits IFN- <mml:math id="M1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi mathvariant="bold-italic">î³</mml:mi></mml:mrow></mml:math> Release by Autologous NK Cells. lournal of Immunology Research, 2014, 2014, 1-7.	2.2	17
52	Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions. Frontiers in Immunology, 2014, 5, 394.	4.8	74
53	Natural Killer Cells and Neuroblastoma: Tumor Recognition, Escape Mechanisms, and Possible Novel Immunotherapeutic Approaches. Frontiers in Immunology, 2014, 5, 56.	4.8	77
54	IL-27 in Human Secondary Lymphoid Organs Attracts Myeloid Dendritic Cells and Impairs HLA Class I–Restricted Antigen Presentation. Journal of Immunology, 2014, 192, 2634-2642.	0.8	20

#	Article	IF	Citations
55	Anti-IgE treatment in asthma: Galectin-3 as a predictive marker. Immunology Letters, 2014, 162, 1.	2.5	3
56	The emerging role of soluble HLA-G in the control of chemotaxis. Cytokine and Growth Factor Reviews, 2014, 25, 327-335.	7.2	29
57	Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. Oncotarget, 2014, 5, 10368-10381.	1.8	18
58	Combining Not-Proper ROC Curves and Hierarchical Clustering to Detect Differentially Expressed Genes in Microarray Experiments. Lecture Notes in Computer Science, 2014, , 238-247.	1.3	0
59	The IL-12RÎ <sup>2</sup> 2 gene functions as a tumor suppressor in human B cell malignancies. Journal of Clinical Investigation, 2014, 124, 2807-2807.	8.2	0
60	Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. Journal of NeuroImmune Pharmacology, 2013, 8, 944-955.	4.1	29
61	CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice. Neuropharmacology, 2013, 75, 337-346.	4.1	25
62	Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. Journal of Controlled Release, 2013, 170, 445-451.	9.9	41
63	Mechanisms of the Antitumor Activity of Human $\hat{V}^39\hat{V}^2$ T Cells in Combination With Zoledronic Acid in a Preclinical Model of Neuroblastoma. Molecular Therapy, 2013, 21, 1034-1043.	8.2	47
64	Plasma Levels of Soluble HLA-E and HLA-F at Diagnosis May Predict Overall Survival of Neuroblastoma Patients. BioMed Research International, 2013, 2013, 1-9.	1.9	30
65	Soluble HLA-G modulates miRNA-210 and miRNA-451 expression in activated CD4+ T lymphocytes. International Immunology, 2013, 25, 279-285.	4.0	10
66	Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients. MAbs, 2013, 5, 801-809.	5.2	66
67	Immunosuppressive Microenvironment in Neuroblastoma. Frontiers in Oncology, 2013, 3, 167.	2.8	61
68	Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity. Journal of Leukocyte Biology, 2013, 94, 183-191.	3.3	13
69	Proteome Profiling of Neuroblastoma-Derived Exosomes Reveal the Expression of Proteins Potentially Involved in Tumor Progression. PLoS ONE, 2013, 8, e75054.	2.5	122
70	Recovery Of Gamma/Delta+ T Cells After Transplantation With Alpha-Beta+/CD19+ Lymphocyte Depleted Hematopoietic Stem Cells From HLA-Haploidentical Donors. Blood, 2013, 122, 3245-3245.	1.4	1
71	Use of the Uteroglobin Platform for the Expression of a Bivalent Antibody against Oncofetal Fibronectin in Escherichia coli. PLoS ONE, 2013, 8, e82878.	2.5	0
72	MYCN: from oncoprotein to tumor-associated antigen. Frontiers in Oncology, 2012, 2, 174.	2.8	16

#	Article	IF	Citations
73	Expression of P2X7 Receptor Increases <i>In Vivo </i> Tumor Growth. Cancer Research, 2012, 72, 2957-2969.	0.9	324
74	Absence of IL- $12R\hat{1}^2$ 2 in CD33+CD38+ pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2R $\hat{1}^3$ C-deficient mice. Leukemia, 2012, 26, 225-235.	7.2	7
75	CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function. Journal of Leukocyte Biology, 2012, 92, 51-58.	3.3	15
76	Structure–activity relationships of novel substituted naphthalene diimides as anticancer agents. European Journal of Medicinal Chemistry, 2012, 57, 417-428.	5.5	44
77	Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy. Science Translational Medicine, 2012, 4, 124ra27.	12.4	531
78	Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration. Journal of Pharmacy and Pharmacology, 2012, 64, 228-236.	2.4	5
79	Ciclesonide modulates in vitro allergen-driven activation of blood mononuclear cells and allergen-specific T-cell blasts. Immunology Letters, 2012, 141, 190-196.	2.5	2
80	Targeting acute myeloid leukemia cells with cytokines. Journal of Leukocyte Biology, 2012, 92, 567-575.	3.3	12
81	Anti-leukemic properties of IL-12, IL-23 and IL-27: Differences and similarities in the control of pediatric B acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology, 2012, 83, 310-318.	4.4	16
82	Close Interactions between Mesenchymal Stem Cells and Neuroblastoma Cell Lines Lead to Tumor Growth Inhibition. PLoS ONE, 2012, 7, e48654.	2.5	23
83	Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke. Current Pharmaceutical Biotechnology, 2012, 13, 59-67.	1.6	7
84	Receptor activator of NF-κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thrombosis and Haemostasis, 2012, 107, 124-139.	3.4	34
85	Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors. Pediatric Blood and Cancer, 2012, 58, 43-49.	1.5	25
86	Bone marrow of neuroblastoma patients shows downregulation of <i>CXCL12</i> expression and presence of <i>IFN</i> signature. Pediatric Blood and Cancer, 2012, 59, 44-51.	1.5	22
87	Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. European Journal of Paediatric Neurology, 2012, 16, 192-195.	1.6	22
88	Bone Marrow-Infiltrating Human Neuroblastoma Cells Express High Levels of Calprotectin and HLA-G Proteins. PLoS ONE, 2012, 7, e29922.	2.5	40
89	Endothelial and Smooth Muscle Cells from Abdominal Aortic Aneurysm Have Increased Oxidative Stress and Telomere Attrition. PLoS ONE, 2012, 7, e35312.	2.5	87
90	Cytokines in neuroblastoma: from pathogenesis to treatment. Immunotherapy, 2011, 3, 895-907.	2.0	23

#	Article	IF	Citations
91	Loss of 10q26.1–q26.3 in association with 7q34–q36.3 gain or 17q24.3–q25.3 gain predict poor outcome in pediatric medulloblastoma. Cancer Letters, 2011, 308, 215-224.	7.2	3
92	Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells. PLoS ONE, 2011, 6, e22739.	2.5	68
93	Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood, 2011, 118, 5840-5850.	1.4	65
94	HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia, 2011, 25, 527-537.	7.2	39
95	A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia, 2011, 25, 1268-1277.	7.2	47
96	Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunology, Immunotherapy, 2011, 60, 1485-1495.	4.2	21
97	Emerging topics and new perspectives on HLA-G. Cellular and Molecular Life Sciences, 2011, 68, 433-451.	5.4	69
98	Damageâ€associated molecular patterns (DAMPs) and mesenchymal stem cells: A matter of attraction and excitement. European Journal of Immunology, 2011, 41, 1828-1831.	2.9	22
99	Disclosing the mysteries of the central nervous system sanctuary for acute lymphoblastic leukemia cells. Leukemia Research, 2011, 35, 699-700.	0.8	3
100	Cytokines as Anti-Angiogenic Agents in Haematological Malignancies. Current Cancer Drug Targets, 2011, 11, 997-1004.	1.6	3
101	Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Research, 2011, 21, 1470-1486.	12.0	66
102	HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology, 2011, 50, 966-972.	1.9	38
103	Identification of Novel Prognostic Markers in Relapsing Localized Resectable Neuroblastoma. OMICS A Journal of Integrative Biology, 2011, 15, 113-121.	2.0	4
104	Dexamethasone Prophylaxis in Pediatric Open Heart Surgery Is Associated with Increased Blood Long Pentraxin PTX3: Potential Clinical Implications. Clinical and Developmental Immunology, 2011, 2011, 1-6.	3.3	11
105	Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. Histology and Histopathology, 2011, 26, 941-51.	0.7	88
106	Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas. Oncotarget, 2011, 2, 976-983.	1.8	68
107	Transient depletion of CD4 <sup>+</sup> T cells augments ILâ€21â€based immunotherapy of disseminated neuroblastoma in syngeneic mice. International Journal of Cancer, 2010, 127, 1141-1150.	5.1	24
108	Potential of mesenchymal stem cells for the therapy of autoimmune diseases. Expert Review of Clinical Immunology, 2010, 6, 211-218.	3.0	33

#	Article	IF	CITATIONS
109	IL-21: a new player in the control of isotype switch in Peyer's patches. Journal of Leukocyte Biology, 2009, 85, 739-743.	3.3	5
110	Interleukin-12 Receptor $\hat{I}^22$ : From Cytokine Receptor to Gatekeeper Gene in Human B-Cell Malignancies. Journal of Clinical Oncology, 2009, 27, 4809-4816.	1.6	27
111	Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides. Journal of Controlled Release, 2009, 138, 122-127.	9.9	13
112	Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens. Stem Cells, 2008, 26, 1275-1287.	3.2	134
113	Tumor Origin of Endothelial Cells in Human Neuroblastoma. Journal of Clinical Oncology, 2007, 25, 376-383.	1.6	131
114	Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G Release. Cancer Research, 2007, 67, 6433-6441.	0.9	100
115	Soluble HLA-G: Are they clinically relevant?. Seminars in Cancer Biology, 2007, 17, 469-479.	9.6	167
116	Lymphoproliferative Disorders and Chemokines. Current Drug Targets, 2006, 7, 81-90.	2.1	12
117	Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon- $\hat{l}^3$ . British Journal of Cancer, 2006, 94, 1845-1852.	6.4	42
118	Lack of HLAâ€class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens, 2001, 57, 110-117.	1.0	61
119	Flow cytometric and functional characterization of AC133+ cells from human umbilical cord blood. British Journal of Haematology, 2000, 108, 793-800.	2.5	36
120	Stromal Cell-Derived Factor-1 as a Chemoattractant for Follicular Center Lymphoma B Cells. Journal of the National Cancer Institute, 2000, 92, 628-635.	6.3	92
121	The Granulocyte Colony-Stimulating Factor (G-CSF)/G-CSF Receptor (G-CSFR) System in B-Cell Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1997, 27, 239-246.	1.3	4
122	Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility- complex-negative human tumour: neuroblastoma. Cancer Immunology, Immunotherapy, 1996, 42, 170-178.	4.2	44
123	Interferon Alfa Therapy in an Infant with Juvenile Chronic Myelogenous Leukemia. Pediatric Hematology and Oncology, 1995, 12, 189-194.	0.8	3